11-07-2025
Kepler Capital Reaffirms Their Hold Rating on GenSight Biologics SA (G49N)
Kepler Capital analyst Justine Telliez maintained a Hold rating on GenSight Biologics SA on July 9 and set a price target of €0.40. The company's shares closed last Tuesday at €0.11.
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telliez covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Adocia SA, and Genfit. According to TipRanks, Telliez has an average return of -4.6% and a 44.90% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for GenSight Biologics SA with a €0.40 average price target.
Based on GenSight Biologics SA's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €897 thousand and a GAAP net loss of €8.15 million. In comparison, last year the company earned a revenue of €248 thousand and had a GAAP net loss of €14.26 million
